Nothing Special   »   [go: up one dir, main page]

HRP20151386T1 - Fenil aminopirimidinski spojevi i njihova primjena - Google Patents

Fenil aminopirimidinski spojevi i njihova primjena Download PDF

Info

Publication number
HRP20151386T1
HRP20151386T1 HRP20151386TT HRP20151386T HRP20151386T1 HR P20151386 T1 HRP20151386 T1 HR P20151386T1 HR P20151386T T HRP20151386T T HR P20151386TT HR P20151386 T HRP20151386 T HR P20151386T HR P20151386 T1 HRP20151386 T1 HR P20151386T1
Authority
HR
Croatia
Prior art keywords
pyrimidin
cyanomethyl
benzamide
morpholinophenylamino
phenylamino
Prior art date
Application number
HRP20151386TT
Other languages
English (en)
Inventor
Christopher John Burns
Andrew Craig Donohue
John Thomas Feutrill
Thao Lien Thi Nguyen
Andrew Frederick Wilks
Jun Zeng
Original Assignee
Ym Biosciences Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ym Biosciences Australia Pty Ltd filed Critical Ym Biosciences Australia Pty Ltd
Publication of HRP20151386T1 publication Critical patent/HRP20151386T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)

Claims (18)

1. Spoj formule Ib [image] u kome je Z je nezavisno odabrano od N i CH; R1 je nezavisno odabran od H, halogena, OH, CONHR2, CON(R2)2, CF3, R2OR2, CN, morfolino, tiomorfolinila, tiomorfolino-1,1-dioksida, supstituiranog ili nesupstituiranog piperidinila, supstituiranog ili nesupstituiranog piperazinila, imidazolila, supstituiranog ili nesupstituiranog pirolidinila i C1-4alkilena u kome su atomi ugljika po izboru zamijenjeni sa NRY i/ili O supstituiranim sa morfolinom, tiomorfolinilom, tiomorfolino-1, 1-dioksidom, supstituiranim ili nesupstituiranim piperidinilom, supstituiranim ili nesupstituiranim piperazinilom, imidazolilom ili supstituiranim ili nesupstituiranim pirolidinilom; R2 je supstituiran ili nesupstituiran sa C1-4alkil; RY je H ili supstituiran ili nesupstituiran C1-4alkil; R8 je RXCN; RX je supstituiran ili nesupstituiran C1-4alkilen u kome do 2 atoma ugljika mogu biti po izboru zamijenjena sa CO, NS2R, NRY, CONRY, SOL, SO2 ili O; R11 je H ili C1-4alkil, U kome su supstituti odabrani iz grupe koja se sastoji od C1-4 alkil, C3-6 cikloalkil, C2-6 alkenil, C2-6 alkinil, C1-6 alkilaril, aril, heterociklil, halo, haloaril, haloheterociklil, hidroksi, C1-4 alkoksi, ariloksi, karboksi, amino, C1-6alkilacil, arilacil, heterociklilacil, acilamino, aciloksi, C1-6alkilsulfenil, arilsulfonil i ciano; ili njegov enantiomer, njegov prolijek ili njegova farmaceutski prihvatljiva sol, gdje su prolijekovi odabrani od: • spojevi u kojima su aminokiselinski ostatak, ili polipeptidni lanac od dva ili više aminokiselinskih ostataka kovalentno vezani peptidnom vezom za slobodnu amino, hidroksi ili karboksilnu grupu spomenutog spojevi formule Ib; • spojevi u kojima su karbonat, karbamat, amid ili alkil estar kovalentno vezani za slobodnu amino, amido, hidroksi grupu ili grupu karboksilne kiseline spomenutog spojevi formule Ib preko karbonilnog ugljika bočnog lanca prolijeka; i • spojevi u kojima je slobodni hidroksil spomenutog spojevi formule Ib pridružen preko veze fosfor-kisik za fosfatni derivat spojevi (kao što je kiselina, sol ili kiselina, ili estar).
2. Spoj prema patentnom zahtjevu 1 gdje R1 je morfolino.
3. Spoj prema patentnom zahtjevu 1 ili patentnom zahtjevu 2 gdje Z je CH.
4. Spoj prema patentnom zahtjevu 1 odabrano od: N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida; N-(2-cianopropan-2-il)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida; N-(cianometil)-4-(2-(3-morfolinofenilamino)pirimidin-4-il)benzamida; N-(cianometil)-4-(2-(4-tiomorfblinofenilamino)pirimidin-4-il)benzamida; N-(cianometil)-4-(2-(4-jodofenilamino)pirimidin-4-il)benzamida; N-(cianometil)-N-(4-(2-(4-morfolinofenilamino)pirimidin-4-il)fenil)metansulfonamida; N-(cianometil)-4-(2-(4-(morfolinometil)fenilamino)pirimidin-4-il)benzamida; N-(2-(cianometilamino)-2-oksoetil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida; N-(cianometil)-4-(2-(4-(4-hidroksipiperidin-1-il)fenilamino)pirimidin-4-il)benzamida; N-(cianometil)-4-(2-(4-(4-metilpiperazin-1-il)fenilamino)pirimidin-4-il)benzamida; N-(cianometil)-4-(2-(4-(3-hidroksipiperidin-1-il)fenilamino)-5-metilpirimidin-4-il)benzamida; 4-(2-(4-(1-benzilpiperidin-4-iloksi)fenilamino)pirimidin-4-il)-N-(cianometil)benzamida; N-(cianometil)-4-(2-(6-morfolinopiridin-3-ilamino)pirimidin-4-il)benzamida; 4-(2-(4-(4-acetilpiperazin-1-il)fenilamino)pirimidin-4-il)-N-(cianometil)benzamida; N-(4-(2-(4-morfolinofenilamino)pirimidin-4-il)fenil)-N-(prop-2-inil)metansulfonamid tozilata; N-(cianometil)-4-(2-(4-(4-hidroksipiperidin-1-il)fenilamino)-5-metilpirimidin-4-il)benzamida; N-(cianometil)-4-(2-(4-(piperidin-4-iloksi)fenilamino)pirimidin-4-il)benzamida; 5-(4-(4-(cianometilkarbamoil)fenil)pirimidin-2-ilamino)-N,N-dimetil-2-morfolinobenzamida; N-terc-butil-5-(4-(4-(cianometilkarbamoil)fenil) pirimidin-2-ilamino)-2-morfolinobenzamida; 5-(4-(4-(cianometilkarbamoil)fenil)pirimidin-2-ilamino)-N-etil-2-morfolinobenzamida; N-(cianometil)-4-(2-(3-fluoro-4-morfolinofenilamino)pirimidin-4-il)benzamida; N-(cianometil)-4-(2-(4-morfolino-3-(trifluorometil)fenilamino)pirimidin-4-il)benzamida; 5-(4-(4-(N-(cianometil)metilsulfonamido)fenil)pirimidin-2-ilamino)-N-(2-(dimetilamino)etil)-2-morfolinobenzamida; N-(cianometil)-N-(4-(2-(4-morfolino-3-(trifluorometil)fenilamino)pirimidin-4-il)fenil)metansulfonamida; N-(cianometil)-4-(2-(3-(propoksimetil)fenilamino)pirimidin-4-il)benzamida; 4-(2-(3-(aliloksimetil)-4-morfolinofenilamino)pirimidin-4-il)-N-(cianometil)benzamida; N-(cianometil)-4-(2-(4-(1-etilpiperidin-4-iloksi)fenilamino)pirimidin-4-il)benzamida; N-(cianometil)-N-(4-(2-(3-fluoro-4-morfolinofenilamino)pirimidin-4-il)fenil)metansulfonamida; N-(4-(2-(3-ciano-4-morfolinofenilamino)pirimidin-4-il)fenil)-N-(cianometil)metansulfonamida; 2-ciano-N-(4-(2-(4-morfolinofenilamino)pirimidin-4-il)fenil)acetamida; N-(cianometil)-4-(2-(4-(2-morfolinoetoksi)fenilamino)pirimidin-4-il)benzamida; N-(cianometil)-4-(2-{[4-(1,1-diokso-1λ6,4-tiomorpholin-4-il)fenil]amino}pirimidin-4-il)benzamida; N-(cianometil)-4-[2-({4-[(1,1-diokso-1λ6,4-tiomorfolin-4-il)metil]fenil}amino)pirimidin-4-il]benzamida; N-(cianometil)-N-metil-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida; i N-(cianometil)-4-(5-metil-2-(4-morfolinofenilamino)pirimidin-4-il)benzamida. i njihove farmaceutsko prihvatljive soli.
5. Spoj prema patentnom zahtjevu 1 koje je [image] ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema zahtjevu 5 koje je hidrohloridna sol slijedećeg spojevi [image]
7. Spoj prema patentnom zahtjevu 1 koje je [image] ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 7, gdje je spoj kinazni inhibitor.
9. Spoj prema patentnom zahtjevu 8, prema kome je kinazni inhibitor JAK2 inhibitor.
10. Proces za pripremu spojevi formule Ib prema patentnom zahtjevu 1, koji sadrži korak vezivanja spojevi formule II [image] gdje je R11 definiran u patentnom zahtjevu 1 i X je klor koji je zatim konvertiran u jod prije vezivanja sa spojevima koja su označena formulama III i IV. [image] pri čemu su Z, R1 i R8 definirani kao što je u patentnom zahtjevu 1; i M je B ili metal.
11. Farmaceutska kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 9, i farmaceutski prihvatljivi nosač.
12. Implant koji sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 9.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, ili farmaceutska kompozicija prema patentnom zahtjevu 11 za primjenu u metodi liječenja bolesti povezanih sa kinazom, gdje spomenuta metoda uključuje davanje efektivne količine spomenutog spoja ili farmaceutske kompozicije subjektu kod koga postoji takva potreba.
14. Spoj ili farmaceutska kompozicija za primjenu kako je traženo u patentnom zahtjevu 13, gdje je bolest povezana sa kinazom imunološka ili inflamatorna bolest, bolest hiperproliferacije, virusno oboljenje, bolest metabolizma, ili vaskularno oboljenje.
15. Spoj ili farmaceutska kompozicija za primjenu kako je traženo u patentnom zahtjevu 14, gdje su imunološko ili inflamatorno oboljenje presađeni organ.
16. Spoj ili farmaceutska kompozicija za primjenu kako je traženo u patentnom zahtjevu 14, gdje je hiperproliferativno oboljenje rak ili mijeloproliferativna bolest.
17. Spoj ili farmaceutska kompozicija za primjenu kako je traženo u patentnom zahtjevu 16 gdje je hiperproliferativna bolest mijeloproliferativna bolest odabrana iz grupe koja se sastoji od slijedećih bolesti: policitemija vera (PV), primarna mijelofibroza, trombocitemija, esencijalna trombocitemija (ET), agnoneična mijeloidna metaplazija (AMM), idiopatska mijelofibroza (IMF), hronična mijeloidna leukemija (CML), sistemska mastocistoza (SM), hronična neutrofilna leukemija (CNL), mijelodisplazni sindrom (MDS) i sistemska bolest masnih ćelija (SMCD).
18. Spoj ili farmaceutska kompozicija za primjenu kako je traženo u patentnom zahtjevu 17, gdje je mijeloproliferativna bolest odabrana iz grupe koju čine policitemija vera (PV), primarna mijelofibroza, trombocitemija, i esencijalna trombocitemija (ET).
HRP20151386TT 2007-03-12 2015-12-16 Fenil aminopirimidinski spojevi i njihova primjena HRP20151386T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89426407P 2007-03-12 2007-03-12
US1625207P 2007-12-21 2007-12-21
PCT/AU2008/000339 WO2008109943A1 (en) 2007-03-12 2008-03-12 Phenyl amino pyrimidine compounds and uses thereof
EP08714386.3A EP2152701B1 (en) 2007-03-12 2008-03-12 Phenyl amino pyrimidine compounds and uses thereof

Publications (1)

Publication Number Publication Date
HRP20151386T1 true HRP20151386T1 (hr) 2016-02-26

Family

ID=39758909

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151386TT HRP20151386T1 (hr) 2007-03-12 2015-12-16 Fenil aminopirimidinski spojevi i njihova primjena

Country Status (22)

Country Link
US (5) US8486941B2 (hr)
EP (2) EP3023422A1 (hr)
JP (5) JP2010520892A (hr)
KR (3) KR101737753B1 (hr)
CN (2) CN104030990B (hr)
AU (1) AU2008226327B2 (hr)
BR (2) BR122020010759B1 (hr)
CA (1) CA2702650C (hr)
CY (1) CY1117180T1 (hr)
DK (1) DK2152701T3 (hr)
ES (1) ES2557930T3 (hr)
HK (1) HK1149749A1 (hr)
HR (1) HRP20151386T1 (hr)
HU (1) HUE029188T2 (hr)
MX (1) MX2009009792A (hr)
PL (1) PL2152701T3 (hr)
PT (1) PT2152701E (hr)
RS (1) RS54533B1 (hr)
RU (1) RU2498983C2 (hr)
SI (1) SI2152701T1 (hr)
WO (1) WO2008109943A1 (hr)
ZA (1) ZA200906848B (hr)

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101737753B1 (ko) * 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
ES2535166T3 (es) * 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
US8309566B2 (en) 2008-02-15 2012-11-13 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
RU2010137300A (ru) * 2008-02-22 2012-03-27 Ф. Хоффманн-Ля Рош Аг (Ch) Модуляторы бета-амилоида
CN102791697A (zh) * 2009-10-12 2012-11-21 瑞科西有限公司 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物
GB201012105D0 (en) 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
CN104473933A (zh) * 2010-12-03 2015-04-01 Ym生物科学澳大利亚私人有限公司 Jak-2 介导的病症的治疗
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CA2826459C (en) * 2011-03-02 2019-09-17 Lead Discovery Center Gmbh Pharmaceutically active disubstituted pyridine derivatives
US8916557B2 (en) 2011-04-19 2014-12-23 Bayer Intellectual Property Gmbh Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines
BR112013028420A2 (pt) * 2011-05-02 2017-01-24 Ym Biosciences Australia Pty tratamento de mieloma múltiplo
TW201636330A (zh) 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
DE102011112978A1 (de) * 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
ES2587284T3 (es) 2011-09-16 2016-10-21 Bayer Intellectual Property Gmbh 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9
WO2013037894A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
US8809359B2 (en) * 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
JP2015536311A (ja) 2012-10-18 2015-12-21 バイエル ファーマ アクチエンゲゼルシャフト スルホン基を含有する4−(オルト)−フルオロフェニル−5−フルオロピリミジン−2−イルアミン
WO2014060375A2 (en) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
MX2015008829A (es) 2013-01-09 2016-04-25 Concert Pharmaceuticals Inc Momelotinib deuterado.
CN103965114B (zh) * 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
EP2986610B9 (en) 2013-04-19 2018-10-17 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
JP2016525071A (ja) * 2013-08-07 2016-08-22 カディラ ヘルスケア リミテッド ヤーヌスキナーゼのインヒビターとしてのn−シアノメチルアミド
JP2016537433A (ja) * 2013-11-26 2016-12-01 ギリアード サイエンシーズ, インコーポレイテッド 骨髄増殖性障害を処置するための治療
EP3080100B1 (en) * 2013-12-11 2022-11-30 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
WO2015109286A1 (en) 2014-01-20 2015-07-23 Gilead Sciences, Inc. Therapies for treating cancers
EP4019518A1 (en) 2014-02-28 2022-06-29 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
TWI681954B (zh) * 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
NZ726360A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
NZ726638A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
HRP20220738T1 (hr) 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
US20170224819A1 (en) 2014-08-11 2017-08-10 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
RS62713B1 (sr) 2014-08-11 2022-01-31 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
CN117088931A (zh) 2014-08-12 2023-11-21 莫纳什大学 定向淋巴的前药
CN104262263B (zh) * 2014-08-29 2017-01-11 西安交通大学 一种N,6二苯基嘧啶-4-胺类Bcr-Abl抑制剂及其制备方法和应用
NZ729618A (en) 2014-09-26 2018-07-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
JP2017531003A (ja) 2014-10-16 2017-10-19 バイエル ファーマ アクチエンゲゼルシャフト スルホン基を含有するフッ化ベンゾフラニル−ピリミジン誘導体
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US20160251376A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN107428707A (zh) 2015-03-24 2017-12-01 拜耳制药股份公司 4‑(4‑氟‑2‑甲氧基苯基)‑n‑{3‑[(s‑甲基亚磺酰亚胺基)甲基]苯基}‑1,3,5‑三嗪‑2‑胺用于治疗多发性骨髓瘤的用途
CN107427520A (zh) 2015-03-24 2017-12-01 拜耳医药股份有限公司 4‑(4‑氟‑2‑甲氧基苯基)‑n‑{3‑[(s‑甲基磺酰亚氨基)甲基]苯基}‑1,3,5‑三嗪‑2‑胺用于治疗淋巴瘤的用途
WO2016150902A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US10023571B2 (en) 2015-09-02 2018-07-17 Nimbus Lakshimi, Inc. TYK2 inhibitors and uses thereof
AU2016318229A1 (en) 2015-09-08 2018-03-29 Monash University Lymph directing prodrugs
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN108290903B (zh) 2015-09-29 2021-09-03 拜耳医药股份有限公司 新的大环磺酰二亚胺化合物
EP3359544B1 (en) 2015-10-08 2020-08-12 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
ES2941969T3 (es) 2015-10-23 2023-05-29 Navitor Pharm Inc Moduladores de la interacción de Sestrina-GATOR2 y sus usos
US11370792B2 (en) 2015-12-14 2022-06-28 Raze Therapeutics, Inc. Caffeine inhibitors of MTHFD2 and uses thereof
DK3827838T5 (en) 2015-12-16 2024-08-19 Walter & Eliza Hall Inst Medical Res Hæmning af cytokin-induceret sh2-protein i nk-celler
EP3426243B1 (en) 2016-03-09 2021-05-19 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
ES2949357T3 (es) 2016-03-09 2023-09-28 Raze Therapeutics Inc Inhibidores de 3-fosfoglicerato deshidrogenasa y usos de los mismos
CN105837515B (zh) * 2016-04-06 2018-08-03 中国药科大学 一种JAK抑制剂Momelotinib的制备方法
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
WO2018031579A1 (en) 2016-08-10 2018-02-15 Gilead Sciences, Inc. Momelotinib for treating of acvr1 -mediated diseases
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018071794A1 (en) 2016-10-14 2018-04-19 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US10647713B2 (en) 2016-10-21 2020-05-12 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
EP3538091A4 (en) 2016-11-08 2020-06-10 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
TW202321243A (zh) 2017-03-08 2023-06-01 美商林伯士拉克許米公司 Tyk2抑制劑之生產方法
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
WO2018177899A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CN110809467B (zh) 2017-04-26 2023-03-10 纳维托制药有限公司 Sestrin-gator2相互作用的调节剂及其用途
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
US11046698B2 (en) 2017-07-28 2021-06-29 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
US11261214B2 (en) 2017-08-04 2022-03-01 Bicycletx Limited Bicyclic peptide ligand specific for CD137
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
US20200291096A1 (en) 2017-08-14 2020-09-17 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
WO2019046491A1 (en) 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein compounds and their uses
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
SG11202002475TA (en) 2017-10-19 2020-04-29 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
WO2019126378A1 (en) 2017-12-19 2019-06-27 Ariya Therapeutics, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. CRBN LIGANDS AND THEIR USES
AU2019212969A1 (en) 2018-01-29 2020-08-13 Merck Patent Gmbh GCN2 inhibitors and uses thereof
CA3089762A1 (en) 2018-01-29 2019-08-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
KR102445054B1 (ko) 2018-02-13 2022-09-22 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EA202091894A1 (ru) 2018-02-13 2020-12-28 Байер Акциенгезельшафт Применение 5-фтор-4-(4-фтор-2-метоксифенил)-n-{4-[(s-метилсульфонимидоил)метил]пиридин-2-ил}пиридин-2-амина для лечения диффузной в-крупноклеточной лимфомы
MX2020008814A (es) 2018-02-27 2020-12-11 Artax Biopharma Inc Derivados de cromeno como inhibidores de la interaccion receptor de antigeno de celula t (tcr) - region no catalitica de la proteina citosolica de la proteina tirosina cinasa (nck).
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
US10815225B2 (en) 2018-04-24 2020-10-27 Merck Patent Gmbh Antiproliferation compounds and uses thereof
CA3097774A1 (en) 2018-04-24 2019-10-31 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof
IL312465A (en) 2018-05-04 2024-06-01 Incyte Corp FGFR inhibitor solid forms and processes for their preparation
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
KR20240074001A (ko) 2018-05-14 2024-05-27 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
JP2021525795A (ja) * 2018-05-25 2021-09-27 カルトス セラピューティクス,インコーポレイテッド 骨髄増殖性腫瘍を治療する方法
RS65761B1 (sr) 2018-06-15 2024-08-30 Janssen Pharmaceutica Nv Analozi rapamicina i njihova upotreba
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
CN108707119A (zh) * 2018-06-25 2018-10-26 抚顺大恒化工有限公司 一种Momelotinib的制备方法
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
JP7578585B2 (ja) 2018-08-21 2024-11-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 骨髄線維症の血小板数非依存的処置方法
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN113164419A (zh) 2018-09-07 2021-07-23 皮克医疗公司 Eif4e抑制剂和其用途
AU2019360941A1 (en) 2018-10-15 2021-04-29 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
MX2021004710A (es) 2018-10-24 2021-06-04 Navitor Pharm Inc Compuestos polimorficos y usos de los mismos.
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
KR20240015737A (ko) 2018-10-30 2024-02-05 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
WO2020112937A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
MX2021006154A (es) 2018-11-30 2021-08-24 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
EP3904356A4 (en) * 2018-12-24 2022-09-21 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. THERAPEUTIC USE OF PYRROLOPYRIMIDINE COMPOUND, AND SOLID PHARMACEUTICAL COMPOSITION OF PYRROLOPYRIMIDINE COMPOUND
AU2020212001A1 (en) 2019-01-23 2021-07-22 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US20220185816A1 (en) 2019-03-14 2022-06-16 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
SG11202110828UA (en) 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
KR20220006139A (ko) 2019-04-05 2022-01-14 카이메라 쎄라퓨틱스 인코포레이티드 Stat 분해제 및 이의 용도
MX2021014441A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2021091535A1 (en) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
WO2020257644A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2020256739A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN110330484B (zh) * 2019-07-18 2022-08-26 中国药科大学 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途
TW202118770A (zh) 2019-07-30 2021-05-16 英商拜西可泰克斯有限公司 異質雙環肽複合物
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin
WO2021050992A1 (en) 2019-09-11 2021-03-18 Vincere Biosciences, Inc. Usp30 inhibitors and uses thereof
WO2021050964A1 (en) 2019-09-13 2021-03-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022008287A2 (pt) 2019-11-01 2022-07-26 Navitor Pharm Inc Métodos de tratamento usando um modulador de mtorc1
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス, インコーポレイテッド ラパマイシン類似体及びその使用
CN114829352B (zh) * 2019-12-16 2024-05-31 昂科比克斯有限公司 新型氘代嘧啶衍生物及包含其的药物组合物
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
CA3161878A1 (en) 2019-12-17 2021-06-24 Matthew M. Weiss Irak degraders and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20220149534A (ko) 2020-02-05 2022-11-08 퓨어테크 엘와이티, 아이엔씨. 신경스테로이드의 지질 전구약물
MX2022010944A (es) 2020-03-03 2022-11-09 Pic Therapeutics Inc Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
BR112022018678A2 (pt) 2020-03-19 2022-11-01 Kymera Therapeutics Inc Degradadores de mdm2 e usos dos mesmos
CN113583020B (zh) * 2020-04-30 2022-04-22 百极弘烨(广东)医药科技有限公司 一种jak2抑制剂及应用
EP4143189A1 (en) 2020-04-30 2023-03-08 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
JP2023538906A (ja) 2020-08-17 2023-09-12 バイシクルティーエクス・リミテッド ネクチン-4に特異的な二環コンジュゲート及びその使用
CN112142675B (zh) * 2020-10-09 2021-11-30 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4255895A1 (en) 2020-12-02 2023-10-11 Ikena Oncology, Inc. Tead inhibitors and uses thereof
EP4267559A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Substituted indole compounds
EP4267562A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
TW202233174A (zh) 2020-12-22 2022-09-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
AU2022216810A1 (en) 2021-02-02 2023-08-24 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Gpr84アンタゴニストおよびその使用
CN114874189B (zh) * 2021-02-05 2023-09-29 深圳市塔吉瑞生物医药有限公司 取代的杂芳基衍生物及其组合物及用途
WO2022173722A1 (en) 2021-02-09 2022-08-18 Gilead Sciences, Inc. Thienopyrrole compounds
CA3207380A1 (en) 2021-02-15 2022-08-18 Haojing RONG Irak4 degraders and uses thereof
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
JP2024513011A (ja) 2021-03-29 2024-03-21 ニンバス サターン, インコーポレイテッド Hpk1アンタゴニスト及びその使用
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法
KR20230172548A (ko) 2021-04-16 2023-12-22 이케나 온콜로지, 인코포레이티드 Mek 억제제 및 이의 용도
CR20230478A (es) 2021-04-16 2023-11-30 Gilead Sciences Inc Compuestos de tienopirrol.
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環
EP4384181A2 (en) 2021-08-10 2024-06-19 GlaxoSmithKline LLC Momelotinib combination therapy
WO2023023473A1 (en) 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用
TWI849499B (zh) 2021-09-10 2024-07-21 美商基利科學股份有限公司 噻吩并吡咯化合物
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
IL314437A (en) 2022-01-31 2024-09-01 Kymera Therapeutics Inc IRAK joints and their uses
WO2023152773A1 (en) * 2022-02-14 2023-08-17 Dr. Reddy's Institute Of Life Sciences Solid forms of momelotinib salts and improved processes for the preparation of momelotinib
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
TW202404581A (zh) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Mek抑制劑及其用途
CN117304179A (zh) * 2022-06-21 2023-12-29 苏州泽璟生物制药股份有限公司 杰克替尼二盐酸盐一水合物的制备工艺
TW202416972A (zh) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 經取代之吡啶酮gpr84拮抗劑及其用途
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024035771A2 (en) * 2022-08-09 2024-02-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Ulk3 inhibitors and uses thereof
CN115677676B (zh) * 2022-10-19 2024-10-01 黑龙江中医药大学 一种治疗银屑病的药物及其制备方法
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2024134481A1 (en) 2022-12-21 2024-06-27 Glaxosmithkline Llc Combination therapy comprising jaktinib

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) * 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
WO2001012210A1 (en) * 1999-08-13 2001-02-22 The Scripps Research Institute Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US20040102455A1 (en) 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
US6949544B2 (en) 2001-03-29 2005-09-27 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
RU2295329C2 (ru) 2001-09-12 2007-03-20 ВиРекс Медикал Корпорейшн Перекрывающее кровоток твердофазное средство с покрытием из иммобилизованного связывающего средства
IL165264A0 (en) 2002-05-23 2005-12-18 Cytopia Pty Ltd Protein kinase inhibitors
EP1546117A2 (en) 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
JP2006512314A (ja) * 2002-11-01 2006-04-13 バーテックス ファーマシューティカルズ インコーポレイテッド Jakインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用
JP4688498B2 (ja) 2002-11-04 2011-05-25 バーテックス ファーマシューティカルズ インコーポレイテッド Jakインヒビターとしてのヘテロアリール−ピリミジン誘導体
EP1560824A1 (en) * 2002-11-05 2005-08-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
WO2005012262A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
GB0317841D0 (en) * 2003-07-30 2003-09-03 Cyclacel Ltd Compound
AR051387A1 (es) * 2004-10-13 2007-01-10 Wyeth Corp Analogos de anilino-pirimidina
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
CA2611720A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Jak­2 조절자로서 4­아릴­2­아미노­피리미딘 또는 4­아릴­2­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
BRPI0708347A2 (pt) 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
FR2911139A1 (fr) * 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
ES2535166T3 (es) * 2007-09-04 2015-05-06 The Scripps Research Institute Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
WO2009073575A2 (en) 2007-11-30 2009-06-11 Oregon Health & Science University Methods for treating induced cellular proliferative disorders
JP2011530517A (ja) 2008-08-05 2011-12-22 ターゲジェン インコーポレーティッド サラセミアを処置する方法
CN104473933A (zh) 2010-12-03 2015-04-01 Ym生物科学澳大利亚私人有限公司 Jak-2 介导的病症的治疗
BR112013028420A2 (pt) 2011-05-02 2017-01-24 Ym Biosciences Australia Pty tratamento de mieloma múltiplo
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof

Also Published As

Publication number Publication date
BRPI0808888B8 (pt) 2021-05-25
BR122020010759B1 (pt) 2021-06-29
CA2702650A1 (en) 2008-09-18
US8486941B2 (en) 2013-07-16
CN101861313A (zh) 2010-10-13
JP2016175934A (ja) 2016-10-06
KR20090128478A (ko) 2009-12-15
KR101737753B1 (ko) 2017-05-18
AU2008226327B2 (en) 2012-12-06
SI2152701T1 (sl) 2016-03-31
RS54533B1 (en) 2016-06-30
US9233934B2 (en) 2016-01-12
HUE029188T2 (en) 2017-03-28
US20220388967A1 (en) 2022-12-08
JP5746388B2 (ja) 2015-07-08
MX2009009792A (es) 2009-09-23
EP2152701A1 (en) 2010-02-17
JP5940700B2 (ja) 2016-06-29
PT2152701E (pt) 2016-01-27
JP2013249316A (ja) 2013-12-12
EP2152701B1 (en) 2015-11-11
RU2498983C2 (ru) 2013-11-20
US20140011803A1 (en) 2014-01-09
ES2557930T3 (es) 2016-01-29
EP2152701A4 (en) 2011-06-22
ZA200906848B (en) 2011-01-26
JP2014114311A (ja) 2014-06-26
CN101861313B (zh) 2014-06-04
BRPI0808888B1 (pt) 2020-11-17
DK2152701T3 (en) 2016-02-15
JP2015145386A (ja) 2015-08-13
EP3023422A1 (en) 2016-05-25
PL2152701T3 (pl) 2016-10-31
KR101566840B1 (ko) 2015-11-06
CN104030990B (zh) 2017-01-04
CA2702650C (en) 2017-01-03
US9238628B2 (en) 2016-01-19
CY1117180T1 (el) 2017-04-05
CN104030990A (zh) 2014-09-10
HK1149749A1 (en) 2011-10-14
RU2009137363A (ru) 2011-04-20
BRPI0808888A2 (pt) 2014-09-02
US20100197671A1 (en) 2010-08-05
JP2010520892A (ja) 2010-06-17
US20210309615A1 (en) 2021-10-07
WO2008109943A1 (en) 2008-09-18
US20140005180A1 (en) 2014-01-02
AU2008226327A1 (en) 2008-09-18
KR20150043565A (ko) 2015-04-22
KR20160106786A (ko) 2016-09-12

Similar Documents

Publication Publication Date Title
HRP20151386T1 (hr) Fenil aminopirimidinski spojevi i njihova primjena
JP6505013B2 (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP5155391B2 (ja) 癌細胞成長抑制用新規アミド誘導体
RU2475487C2 (ru) Имидазохинолины с иммуномодулирующими свойствами
IL277183B2 (en) Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
NZ605988A (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
JP2017515844A5 (hr)
JP2009519979A5 (hr)
NZ589843A (en) Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors
HRP20130174T1 (hr) Derivati pirimidina za lijeäśenje astme, kopb, alergijskog rinitisa, alergijskog konjuktivitisa, atopijskog dermatitisa, karcinoma, hepatitisa b, hepatitisa c, hiv, hpv, bakterijskih infekcija i dermatoze
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
RU2016146365A (ru) Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
JP2014511869A5 (hr)
RU2009126624A (ru) Производные 2-(пиперидин-4-ил)-4-фенокси-или фенилаинопиримидина в качестве ненуклеозидных ингибитров обратной транскриптазы
US11597704B2 (en) 2,4-diaminoquinazoline derivatives and medical uses thereof
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
HRP20211722T1 (hr) Supstituirani spojevi pirazolo[1,5-a]pirimidina kao inhibitori trk kinaze
JP2013510876A5 (hr)
RU2013139353A (ru) Трициклические пирролопроизводные, способ их получения и их применение в качестве ингибиторов киназы
JP2012501313A5 (hr)
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
HRP20120735T1 (hr) Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora
WO2015038778A1 (en) SUBSTITUTED UREA EIF2α KINASE ACTIVATORS
AR051735A1 (es) Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos.
AR074855A1 (es) Derivados aminoester de alcaloides y composicion medicinal de los mismos utilizadas en el tratamiento de enfermedades mediadas por el antagonismo de los receptores muscarinicos.